Skip to main content
. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766

Figure 2.

Figure 2

Cumulative incidences of Grade II-IV and Grade III-IV acute GVHD. (A) Cumulative incidences of Grade II-IV acute GVHD: CAR-T group: 48.1% (95% CI:46.1, 50.1%) vs. chemotherapy group: 25.6% (95% CI: 25.2, 26.0%); p=0.016. (B) Cumulative incidences of Grade III-IV acute GVHD: CAR T-cell group: 11.1% (95% CI: 10.3, 11.9%) vs. chemotherapy group: 11.5% (95% CI: 11.3, 11.7%); p=0.945. (C) Cumulative incidences of Grade II-IV acute GVHD: CRS Grade 0-I 47.4% (95% CI: 44.7, 50.1%) vs. CRS Grade II-IV: 50.0% (95% CI:42.6, 57.4%); p=0.95. (D) Cumulative incidences of Grade III-IV aGVHD: CRS Grade 0-I: 10.5% (95% CI: 9.5, 11.5%) vs. CRS Grade II-IV: 12.5% (95% CI: 9.4, 15.6%); p=0.92.